Temple University requires students from countries with a high incidence of tuberculosis (TB) to be screened for TB. There are two types of TB testing, a blood test (IGRA, interferon gamma release assay) and a skin test (Mantoux skin test or PPD). PPD results must be reported in millimeters induration. Both tests are acceptable though the IGRA test is preferred in people who have received a TB vaccine (BCG) in childhood.
A positive test result will not preclude you from registering or participating in classes. If testing is positive, a chest x-ray will be required. TB testing and x-rays must be completed within 6 months of starting classes at Temple. We will accept test and chest x-ray results from a medical provider in your home country if they are printed in English. Please upload these results through the Uploads tab of your Patient Health Portal (use the Immunization record or HSC and CPH Immunization, Titer And-Or Physical Record option).
If you cannot get testing while at home, it can be done at Student Health Services (and needs to be completed in the first semester of enrollment). We can bill your insurance, or you can pay the out-of-pocket student cost. A list of these costs can be found at this https://studenthealth.temple.edu/appointments/prices
If you have any questions after reviewing this information, or to schedule an appointment, please call 215-204-7500 and ask to speak with a nurse. You can also email Student Health: SHS@temple.edu
To learn more about TB testing, please go to this website
https://www.cdc.gov/tb/risk-factors/country.html
Countries of High Incidence include:
| Afghanistan | Greenland | Northern Mariana Islands Pakistan |
| Algeria | Guam | Palau |
| Angola | Guatemala | Panama |
| Argentina | Guinea | Papua New Guinea |
| Armenia | Guinea-Bissau | Paraguay |
| Azerbaijan | Guyana | Peru |
| Bangladesh | Haiti | Philippines |
| Belize | Honduras | Qatar |
| Benin | India | Romania |
| Bhutan | Indonesia | Russian Federation |
| Bolivia (Plurinational State of) Bosnia and Herzegovina Botswana | Iraq | Rwanda |
| Brazil | Kazakhstan | Sao Tome and Principe |
| Brunei Darussalam | Kenya | Senegal |
| Burkina Faso | Kiribati | Sierra Leone |
| Burundi | Korea (Democratic People’s Republic of) Korea (Republic of) | Singapore |
| Cabo Verde | Kyrgyzstan | Solomon Islands |
| Cambodia | Lao People's Democratic Republic Latvia | Somalia |
| Cameroon | Lesotho | South Africa |
| Central African Republic Chad | Liberia | South Sudan |
| China | Libya | Sri Lanka |
| China, Hong Kong SAR | Lithuania | Sudan |
| China, Macao SAR | Madagascar | Suriname |
| Colombia | Malawi | Syrian Arab Republic |
| Comoros | Malaysia | Tajikistan |
| Congo | Maldives | Tanzania (United Republic of) Thailand |
| Congo (Democratic Republic of) Cote d'Ivoire | Mali | Timor-Leste |
| Djibouti | Marshall Islands | Togo |
| Dominican Republic | Mauritania | Trinidad and Tobago |
| Ecuador | Mexico | Tunisia |
| El Salvador | Micronesia (Federated States of) Moldova (Republic of) | Turkmenistan |
| Equatorial Guinea | Mongolia | Tuvalu |
| Eritrea | Morocco | Uganda |
| Eswatini | Mozambique | Ukraine |
| Ethiopia | Myanmar | Uruguay |
| Fiji | Namibia | Uzbekistan |
| French Polynesia | Nauru | Vanuatu |
| Gabon | Nepal | Venezuela (Bolivarian Republic of) Viet Nam |
| Gambia | Nicaragua | Yemen |
| Georgia | Niger | Zambia |
| Ghana | Nigeria | Zimbabwe |
| Niue |
* Taken from Appendix B: 2026 High-Incidence Country List: https://www.acha.org/wp-content/uploads/ACHA_TB-Risk-Assessment-and-Management-Guidelines_MAY-2026.pdf